Signalling through tyrosine kinase (TK) receptors including vascular endothelial growth factor (VEGF) receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) plays a critical role in tumour angiogenesis [5], and consequently, inhibiting these receptors has emerged as a compelling approach for cancer treatment. This evidence concerns the gene KDR and neoplasm.